SUNNYVALE, Calif., July 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the appointment of leading molecular epidemiologist and expert on Healthcare Associated Infections, Fred Tenover, Ph.D., as Senior Director of Scientific Affairs. Dr. Tenover will serve as a liaison with the Infection Control community and will lead Cepheid's Healthcare Associated Infection (HAI) Consortium program.
"The objective of the Cepheid HAI Consortium is to establish global connections between hospital laboratories and leading academic laboratories in order to track evolving drug resistance patterns, virulence determinants, and the emergence of new strains associated with specific HAIs. The resulting information will be used in the design of rapid and definitive new tests for HAIs and for ensuring that Cepheid's leadership position in this area is maintained and expanded," said David H. Persing, M.D., Ph.D., Chief Medical and Technology Officer at Cepheid. "Dr. Tenover is a noted microbiologist and authority on HAI-associated organisms and as such, is uniquely qualified to head Cepheid's HAI Consortium Program. I am extremely pleased to welcome such an accomplished scientist to our team and look forward to Fred's contribution as we continue to expand and refine our menu of molecular tests in this important developing market."
Dr. Tenover currently holds the position of Distinguished Consultant and Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention, Atlanta, GA. In addition, Dr. Tenover is Director, Centers for Disease Control and Prevention/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring, Atlanta, GA and is Adjunct Professor in the Department of Epidemiology, Emory University School of Public Health, Atlanta, GA.
"Finding effective treatment for the increasing number of multiple
antibiotic resistant HAIs has become a serious challenge for physicians not
Copyright©2008 PR Newswire.
All rights reserved